KR20190105387A - Micell for transdermal absorption and composition for transdermal absorption comprising the same - Google Patents

Abstract

The present invention relates to a micelle for transdermal absorption and a composition for transdermal absorption comprising the same. More specifically, the present invention relates to a micelle for transdermal absorption, comprising an amphiphilic copolymer and an anisotropic lipid, and a composition for transdermal absorption comprising the micelle for transdermal absorption.

Description

Percutaneous absorption micelles and transdermal absorption compositions comprising the same {MICELL FOR TRANSDERMAL ABSORPTION AND COMPOSITION FOR TRANSDERMAL ABSORPTION COMPRISING THE SAME}

The present invention relates to a transdermal absorption micelle and a cosmetic composition comprising the same, and more particularly, a transdermal absorption micelle with improved skin absorption as the form of the micelle is deformable due to increased softness. It relates to a cosmetic composition.

Products using the penetration / penetration technology of active ingredients through the skin are commercially available in a variety of cosmetic and pharmaceutical fields. In particular, multiple methods have been implemented to increase skin permeability in this mode of delivery, for example, the method of sealing and delivering the active ingredient in the microparticles, the method of sealing and delivering the phospholipids or derivatives thereof, surfactants and cell penetrating peptides. And the like are used.

Among them, a technique for forming a polymer micelle by using a method widely used in recent years and encapsulating the active ingredient in the micelle has been in the spotlight. As an example of the polymer used to form the polymer micelle, a block copolymer made of a hydrophilic polymer and a hydrophobic polymer may be used. In this case, a fat-soluble drug may be contained in a high content and solubilized.

For example, Republic of Korea Patent Publication No. 2014-0033676 is composed of a hydrophobic block (A), a hydrophilic block (B) and a binding block (C), the cell permeable peptide (P) to the binding block (C) chemically bonded A multi-block copolymer-cell permeable peptide conjugate is disclosed. However, conventional micelles use amphiphilic block polymers such as, for example, commercially available PEG-PCL, and these block polymers are characterized by amphipathic properties and have self-associating properties and are structurally very stable in various cosmetic formulations. . However, this strong structure can rather have a negative impact in terms of skin absorption.

For example, PCL blocks in PEG-PCL block polymers rather interfere with intercellular pathways through the keratinous intercellular lipid layer due to their crystalline phase formation. Therefore, the carrier having low crystallinity and high strain rate exhibits excellent skin absorption performance. In addition, new materials that are chemically bound, such as block polymer-cell permeable peptide conjugates, have been researched and developed to increase skin absorption, but have a limitation on transdermal absorption due to the rigid structure due to crystallinity as mentioned above. have.

Therefore, when polymer micelles with improved skin absorption performance are developed by geometrically obstructing the regular chain orientation of the polymer micelles, they are structurally deformable and are deeply absorbed into the stratum corneum, thus maximizing skin delivery ability. It is expected to be possible.

Accordingly, one aspect of the present invention is to provide a deformable transdermal absorption micelle with increased softness.

Another aspect of the present invention is to provide a transdermal absorption composition including the transdermal absorption micelle with improved absorption.

According to one aspect of the present invention, a transdermal absorption micelle comprising an amphiphilic copolymer and an anisotropic lipid is provided.

According to another aspect of the present invention, there is provided a transdermal absorption cosmetic composition comprising the transdermal absorption micelle of the present invention.

According to the present invention, a polymer micelle nanocarrier having controlled fluidity and peptide interaction is provided, and the polymer micelle is structurally deformable and can be absorbed more deeply into the stratum corneum, thereby enhancing the skin transfer ability of the nanocarrier. It can be maximized.

Figure 1 schematically shows the manufacturing process of the polymer nano-carrier.
Figure 2 (a) shows the synthesis of the MEL-based peptide linker, Figure 2 (b) and Figure 2 (c) is the target of the ¹ H-NMR spectrum before and after incorporation of the maleimide peptide linker into the MEL Indicates that the material is well synthesized.
Figure 3 (a) shows the hydrodynamic particle size of the polymer nano-carrier according to the various MEL content (φ MEL) in the ratio of PEO-b-PCL / MEL, Figure 3 (b) is φ MEL = 0 3 (c) shows the TEM image of the polymer nanocarrier when φMEL = 0.2 and FIG.3 (d) when φMEL = 0.5.
4 (a) shows that the crystallinity of the PCL decreases as the MEL content increases as a result of the XRD spectrum of the PEO-b-PCL / MEL mixture having various φ MEL. Figure 4 (b) shows the DSC curve, (a) φ MEL = 0, (b) φ MEL = 0.05, (c) φ MEL = 0.1, (d) φ MEL = 0.2, and (e) φ MEL = 0.3 As shown in (a), the crystallinity of PCL decreases as the content of φMEL increases, and it can be seen that it is consistent with the XRD result. 4 (c) shows the T ₂ relaxation time of PEO-b-PCL / MEL nanocarriers with various MELs.
5 shows the rheological behavior of 20 wt% PEO-b-PCL / MEL micelles. Fig. 5 (a) shows the viscosity behavior as a function of shear rate, and Fig. 5 (b) shows the storage modulus, G '(closed symbol) and loss modulus as a function of oscillation strain. , G '' (open symbol).
Figure 6 (a) shows the chemistry between the TAT and MEL linker having a cysteamide group at the end, Figure (b) shows the cell uptake of the nanocarrier containing a Nile red fluorescent probe. In this case, the Nile red value obtained by flow cytometry showed changes in the composition of the nanocarriers, and (a) to (e) were (a) φMEL = 0, (b) φMEL = 0.2, and φMEL = 0.2 and With TAT (c) 50 M, (d) 100 M, and (e) 200 M together. Figure 6 (c) is a fluorescence microscopy image of fibroblasts treated with 100 μM TAT, (a) propylene glycol / ethanol, (b) PEO-b-PCL nano vehicle (φMEL = 0), and (c) TAT It relates to a squashy PEO-b-PCL / MEL nanovehicle (φMEL = 0.2, TAT = 100 μM) comprising a.

Hereinafter, with reference to the accompanying drawings will be described a preferred embodiment of the present invention. However, embodiments of the present invention may be modified in various other forms, and the scope of the present invention is not limited to the embodiments described below.

The present invention provides a transdermal absorption micelle, which is a nanocarrier that maximizes skin transfer ability by improving soft properties in a polymer-based rigid micelle structure.

More specifically, the transdermal absorption micelles of the present invention comprise amphiphilic copolymers and anisotropic lipids.

The amphiphilic copolymer is a polycaprolactone-polyethylene glycol (PCL-PEB) copolymer and the ratio and molecular weight of PCL / PEG can be adjusted in various ways to obtain physical properties suitable for the purpose. It lowers the high crystallinity of PCL, introduces anisotropic lipids to increase the flexibility of the nanocarriers, and these lipids may be glycolipids and / or phospholipids, which anisotropic lipids are for example mannosylerythritol lipids (mannosylerythritol lipids (MEL). Such anisotropic lipids have molecular anisotropy due to the different lengths of the hydrophobic alkyl chains, and by introducing lipids having such a structure, geometrical interference with the regular chain orientation of the polymer micelles improves skin absorption performance. The micelle, which is a nanocarrier, can be obtained.

Furthermore, the transdermal absorption micelle of the present invention preferably further comprises a cell penetrating peptide (CPP), wherein the cell penetrating peptide is a natural such as Tat peptide (Transactivator of transcription peptide), VP22, transportain, polyarginine, etc. Derived and novel synthetic cell permeation peptides and the like, preferably using Tat peptides.

On the other hand, the cell permeable peptide is preferably bound to anisotropic lipids, wherein the process of binding the cell permeable peptide to the anisotropic lipid is not particularly limited, any method known in the art can be used. For example, micelles in which cell-permeable peptides are conjugated are prepared using a maleimide-thiol reaction, which is a representative reaction of peptide conjugation, by replacing a hydroxyl group of anisotropic lipid with a peptide linker. can do. This exemplary process is shown schematically in FIG. 1.

In the present invention, the average particle diameter of the micelles may be 20-100nm, preferably 40-60nm. If the particle size of the micelle is less than 20nm, there is a toxicity problem due to absorption in the human body, if it exceeds 100nm may have a problem that is not well absorbed by the skin.

On the other hand, the content of the anisotropic lipid may be 5 to 40% by weight, preferably 5 to 30% by weight based on the total weight of the amphiphilic copolymer and the anisotropic lipid. When the content of the anisotropic lipid is less than 5% by weight, the size reduction effect of the micelle particles is insignificant and problematic, and even if the content of more than 40% by weight, there is also a problem that the reduction of micelle particles is insignificant.

More specifically, in the polymer-lipid hybrid micelle, the particle size decreases as the concentration of the anisotropic lipid increases due to the interfacial force of the anisotropic lipid itself (Fig. 3 (a)), and the micelle particles have a capillary force ( Capillary forces make it structurally deformable. On the other hand, the micelle anisotropic lipid is separated from the polymer and the lipid phase above a certain concentration (Figs. 3 (b) to 3 (d)).

Furthermore, when the transdermal absorption micelle of the present invention includes a cell permeable peptide, the content of the cell permeable peptide may be 50 μM to 200 μM, and preferably 75 μM to 150 μM. If the content of the cell permeable peptide is less than 50μM effect is insignificant problem, if it exceeds 200μM there is a problem of cytotoxicity.

Furthermore, according to another aspect of the present invention, there is provided a transdermal absorption cosmetic composition comprising the transdermal absorption micelle of the present invention. The percutaneous absorption composition of the present invention is not particularly limited in use, and may be, for example, a cosmetic composition, a pharmaceutical composition, a food composition, and the like.

On the other hand, the cosmetic composition of the present invention is an emulsion, lotion, ointment, patches, sprays, creams (oil-in-water, water-in-oil, multiphase), solutions, suspensions (anhydrous and aqueous), anhydrous products (oil and glycols) Formulations, such as gels, masks, packs or powders, and the formulations are not particularly limited. At this time, other components except for the transdermal absorption micelle of the present invention may be appropriately selected by those skilled in the art according to the formulation or purpose of use.

In more detail, the cosmetic composition of the present invention is an external skin ointment, cream, supple cosmetics, nourishing cosmetics, pack, essence, hair tonic, shampoo, conditioner, hair conditioner, hair treatment, gel, skin lotion, skin softener, skin toner , Astringent, Lotion, Milk Lotion, Moisture Lotion, Nutrition Lotion, Massage Cream, Nutrition Cream, Moisture Cream, Hand Cream, Foundation, Nutrition Essence, Sunscreen, Soap, Cleansing Foam, Cleansing Lotion, Cleansing Cream, Body Lotion and Body Cleanser It may have any one formulation selected from the group consisting of, but is not limited thereto. The cosmetic composition consisting of each of these formulations may contain various bases and additives necessary for the formulation of the formulation and are suitable, and the type and amount of these components can be easily selected by those skilled in the art.

On the other hand, transdermal absorption composition comprising the percutaneous absorption micelle of the present invention may include an active ingredient for transdermal delivery in the micelle, wherein the active ingredient is not particularly limited, for example, various whitening ingredients, wrinkles It may be a skin cosmetic ingredient including an improving ingredient, a homeostatic ingredient, an anti-aging ingredient, a moisturizing ingredient, or the like, or a pharmaceutical ingredient.

For example, within the micelle of the present invention, at least one component selected from the components characterized by fat solubility, for example, a component such as retinol which is effective for wrinkles, may be collected.

The composition of the present invention may comprise an acceptable carrier in cosmetic preparations in addition to the active ingredient. Herein, "acceptable carrier in cosmetic preparation" means a compound or composition already known and used that can be included in a cosmetic preparation, or a compound or composition to be developed in the future, which has no toxicity above the adaptable toxicity to the human body upon contact with the skin. The carrier may be included in the composition of the present invention in an amount of 100% by weight, based on the total weight thereof, of the balance of the extract of the present invention.

The specific content of the carrier included in the cosmetic composition of the present invention will vary depending on the formulation of the above-mentioned cosmetics and its specific application site (face or hand) or its preferred application amount.

Meanwhile, examples of the carrier include alcohols, oils, surfactants, fatty acids, silicone oils, wetting agents, moisturizers, viscosity modifiers, emulsions, stabilizers, sunscreen agents, colorants, fragrances, and the like. Alcohols, oils, surfactants, fatty acids, silicone oils, wetting agents, moisturizers, viscosity modifiers, emulsions, stabilizers, sunscreens, colorants, fragrances, compounds or compositions which can be used as the carrier are already known in the art. Therefore, those skilled in the art can select and use appropriate materials or compositions.

More specifically, when the formulation of the cosmetic composition of the present invention is a paste, cream or gel as a carrier component, animal fibers, plant fibers, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, Talc or zinc oxide may be used.

When the formulation of the cosmetic composition of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as the carrier component, and in particular, in the case of a spray, additionally chlorofluorohydro Propellants such as carbon, propane-butane or dimethyl ether.

When the formulation of the cosmetic composition of the present invention is a solution or emulsion, a solvent, solvating agent or emulsifying agent is used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene Fatty acid esters of glycol, 1,3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.

When the formulation of the cosmetic composition of the present invention is a suspension, as a carrier component, water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Microcrystalline cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.

When the formulation of the cosmetic composition of the present invention is a surfactant-containing cleansing agent, the carrier component is an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, acethionate, an imidazolinium derivative, a methyltaurate, or a sarcosinate. Fatty acid amide ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.

The cosmetic composition of the present invention may further contain an excipient including a fluorescent substance, a fungicide, a caustic agent, a moisturizer, a fragrance, a fragrance carrier, a protein, a solubilizer, a sugar derivative, a sunscreen agent, a vitamin, a plant extract, .

The transdermal absorption composition of the present invention preferably comprises a transdermal absorption micelle in an amount of 0.1 to 10% by weight based on the total weight of the composition. When the transdermal absorption micelle is included in less than 0.1% by weight based on the total weight of the composition, the effect is insignificant, and when included in excess of 10% by weight, there is a toxicity problem.

Hereinafter, the present invention will be described in more detail with reference to specific examples. The following examples are merely examples to help understanding of the present invention, but the scope of the present invention is not limited thereto.

Example

1. Material

The poly (ethylene oxide) -b -poly (ε-caprolactone) copolymer (PEO-b-PCL) used in the present invention was obtained from ACT (South Korea). Mannosylerythritol lipids (MEL) were obtained from Damichem (Korea). TAT peptide (YGRKKRRQRRR-cysteamine) was purchased from Peptron (Daejeon, South Korea). N, N-diisopropylethylamine (TCI, Japan) was used as the base. 4-nitrophenylchloroformate, methylene chloride, ammonium chloride (NH ₄ Cl), magnesium sulfate (MgSO ₄ ), acetonitrile, N- (2-aminoethyl) maleimide trifluoroacetate salt, ethyl acetate (EtOAc) And n-hexane were all purchased from Sigma-Aldrich (USA). Tetrahydrofuran (> 98%, TCI, Japan) was used as a removable solvent. Retinol (Retinol 50C, 50% mixture in Tween 20, BASF, Germany) was used as a model drug. In all experiments, deionized double distilled water was used.

2. Nanocarriers Micelle  Produce

(1) Synthesis of Peptide Linkers Based on MEL

To conjugate CPP to the polymer nanocarriers, MEL with peptide linker moiety was synthesized via a two step organic synthesis reaction.

In the first step, the round bottom flask was filled with MEL (1 g) and purged with nitrogen. Anhydrous methylene chloride (32 mL), pyridine (367 μL) and N, N-diisopropylethylamine (87 μL) were added sequentially to the flask. The solution obtained by adding 4-nitrophenylchloroformate (551 mg) in anhydrous methylene chloride (4 mL) through a syringe to the mixture was stirred at room temperature for 2 minutes. Saturated (aq) NH ₄ Cl was added and the layers were separated. The aqueous layer was extracted twice with methylene chloride. The organic layers were combined, dried over MgSO ₄ , filtered and concentrated using a rotary concentrator. The residue was purified by flash column chromatography on silica gel to give orthoformate Compound (1) (750 mg) as a colorless oil.

In a second step a round bottom flask was filled with the orthoformate compound (1) (100 mg). The flask was evaporated and backfilled with nitrogen. Acetonitrile (2.8 mL) was subsequently added N, N-diisopropylethylamine (73 μL). N- (2-aminoethyl) maleimide trifluoroacetate salt (53 mg) was added in a single portion and reacted with stirring for 12 hours at room temperature. The solvent was removed under reduced pressure. The residue was dissolved in methylene chloride and then concentrated using a rotary concentrator. The residue was purified by flash column chromatography on silica gel (EtOAc: n-hexane = 1: 2) to afford maleimide (2) (56 mg) as a colorless oil.

(2) Preparation of TAP-Attached Polymer Nanocarriers

For the preparation of polymeric nanocarriers, PEO-b-PCL, MEL, and MEL-based peptide linkers were sonicated at 40 ° C. for 10 minutes and completely dissolved in THF. Subsequently, deionized water (purified water, DI water) was added dropwise to the mixture with vigorously stirring. In this process a syringe pump (Pump11Elite, Harvard Apparatus, USA) with a flow rate of 100 μL min ⁻¹ was used. Nanocarriers were prepared by self-assembly of PEO-b-PCL, MEL, and MEL-based peptide linkers. The concentrations of PEO-b-PCL and MEL were maintained to be 3w / v% based on the total volume of nanocarrier dispersion. MEL-based peptide linker was set to 200 μM. THF was completely controlled by evaporation at 40 ° C. Thereafter, a controlled amount of TAT was added to the nanodispersion with gentle stirring at room temperature for 12 hours. This synthesis process is shown schematically in FIG. 1.

(3) polymer nanocarrier structure

MEL has an asymmetric molecular structure from two hydrophobic alkyl chains having different carbon numbers. This unique molecular structure smoothes the hydrophobic core because the co-assembly of MEL and PEO-b-PCL effectively inhibits the molecular affinity of the PCL block.

In order to maximize the skin transfer ability of the nanocarrier, TAT peptide (TATp) conjugation, a kind of CPP (cell penetrating peptide), was performed on nano micelles. In order to conjugate CPP, synthesis was performed in which a hydroxyl group of MEL was substituted with a peptide linker. At this time, a micelle in which TATp was conjugated was prepared using a maleimide-thiol reaction, which is a typical reaction of peptide conjugation (FIG. 2 ( a)). Successful synthesis of the MEL-based peptide linker was confirmed by 1 H-NMR analysis as shown in FIGS. 2 (b) and 2 (c). The yield was ~ 34.2%.

3. Characteristics of Nanocarriers

(1) How to check the characteristics

Crystallinity of the PEO-b-PCL / MEL mixture was confirmed using an X-ray diffractometer (XRD, Rigaku, Japan) with two theta / theta scanning modes, 40 kV / 100 mA X-ray and RINT 2000 wide angle goniometer It was. In the measurement, 2θ was varied between 5 ° and 40 °. The thermal properties of the PEO-b-PCL / MEL mixtures were measured using differential scanning calorimetry (DSC, Universal V4.3A, TA Instrument, USA). The heating rate was controlled at 10 ° C./min at temperatures between −50 ° C. and 100 ° C. under nitrogen flow. The heat flow was determined using the melting point of each sample. The particle size and zeta potential of the polymeric nanocarriers were measured at 25 ° C. by dynamic light scattering (DLS, ELS-Z, Otsuka electronics, Japan). To avoid multiple scattering effects, all samples were diluted with water prior to droplet size measurement. The shape of the emulsion droplets was analyzed by transmission electron microscope (TEM, Energy-Filtering Transmission Electron Microscope, LIBRA 120, Carl Zeiss, Germany) at 120 kV. All test samples were negatively stained with 1 wt% uranyl acetate before TEM analysis.

(2) Particle size change of polymer micelle vehicle according to MEL content

The particle size of the polymer micelle vehicle was confirmed by using transmission electron microscopy (TEM) as the MEL weight fraction ( _MEL ) in the PEO-b-PCL / MEL mixture changed from ˜80 nm to ˜40 nm. 3 (a)). The PEO-b-PCL nanovehicle showed a spherical particle shape with an average particle diameter of ˜75 nm (FIG. 3 (b)). Maintaining the spherical shape of particles means that they form a solid phase that can withstand the burden of capillary forces during the dyeing process. The introduction of MEL not only induces a less homogeneous phase vehicle but also allows the particle morphology to be modified (FIG. 3 (c)). When an excess of MEL was introduced (φ _MEL = 0.5), particles having a particle diameter of 40-80 nm were observed (Fig. 3 (d)).

That is, in the polymer-lipid hybrid micelle, the size of the particles decreased as the concentration of MEL increased due to the interfacial activity of the MEL itself (Fig. 3 (a)). It can be seen through the TEM analysis that structurally deformable (deformable). In addition, it was confirmed that the phase of the polymer and the lipid is separated above a specific concentration of MEL in the micelle ((FIG. 3 (b) to (d))).

4. of high density suspension Rheology  Measure

(1) rheology measurement method

에서 수행되었다. 진동폭의 변형률 범위(strain range)는 0.01-100 %였다. The interaction between the particles was observed by the rheology of the high density suspension. For this purpose, a DHR-1 rheometer (TA instrument, USA) was used in a stress control mode with a cone-plate geometry of 40 mm diameter and 2 ° angle. The concentration of the polymer nanocarrier in water was adjusted to 20 w / v% through evaporation of water. Dispersion was equilibrated for 10 minutes prior to operation of the rheometer. Solvent traps were installed around the test sample to prevent evaporation of water from the dispersion system. Suspension rheology was measured by running flow sweep, oscillation amplitude. The flow? Measurements are shear rate in the range of 0.001 to 100

Was performed in. The strain range of the vibration width was 0.01-100%.

(2) rheological measurement result

Rheological analysis was conducted to determine the effect of MEL on the particle-particle interactions. In the absence of MEL, the dispersion of PEO-PCL showed a viscosity-dependent viscosity behavior, and the dispersion of PEO-PCL arranged with MEL was about 10 times higher in viscosity, and more storage modulus than loss modulus (G "). The high (G ') value indicates that the elastic properties were increased.

5. Experimental application of nanocarriers to fibroblasts

(1) Experiment Method

Human dermal fibroblast GM01651 was obtained from Coriell Cell Repository (Camden, NJ), including Earle's (MEM / EBSS; Hyclone, Logan, UT) and containing 15% fetal bovine serum (FBS; Gibco, Rockville, MD), 2 mM L At 37 ° C., 5% CO ₂ conditions in minimal essential nutrient medium fed with glutamine (Gibco, Rockville, MD), 0.1 mM non-essential amino acids (Sigma, St. Louis, Mo), and 1% penicillin-streptomycin Incubated. All cell culture plates or coverglasses were coated with 0.1% gelatin before cell plating experiments. Nanocarriers were diluted using PBS solution before use. For cultured fibroblasts, the media was removed from the cell culture plates for nanocarrier treatment and 96 well plates (3.5 x 10 ³ cells) or 48 well plates (8.2 x 10 ³ ) for 1 hour in 200 μl nanocarrier solution. cells). After washing twice with Dulbecco's phosphate buffered saline (DPBS; Welgene, Korea), fluorescence was measured using a microplate reader (BioTek, Winooski, VT) at 552 nm. For immunocytochemistry, coverglasses of cultured cells were fixed for 15 minutes in 3.7% formaldehyde and washed twice with DPBS solution. Fluorescence images were taken using a Zeiss LSM800 confocal microscope (ZEISS, Oberkochen, Germany).

(2) experimental results

Intracellular permeability of micelles with Tat peptide conjugated using human fibroblasts and fluorescent dye Nilered showed high cell permeability in order of CPP-containing polymer-lipid micelle, polymer-lipid micelle, and polymer micelle. When the concentration is 10 μM, it was confirmed that the cell permeability improved about 30 times compared to the polymer micelle (Fig. 6).

Although the embodiments of the present invention have been described in detail above, the scope of the present invention is not limited thereto, and various modifications and changes can be made without departing from the technical spirit of the present invention described in the claims. It will be obvious to those of ordinary skill in the field.

Claims (12)

A transdermal absorption micelle comprising an amphiphilic copolymer and an anisotropic lipid.
The transdermal absorption micelle of claim 1, further comprising Cell penetrating peptide (CPP).
The transdermal absorption micelle according to claim 2, wherein the cell permeable peptide is bound to an anisotropic lipid.
The transdermal absorption micelle according to claim 1, wherein the amphiphilic copolymer is a polycaprolactone-polyethylene glycol (PCL-PEB) copolymer.
The transdermal absorption micelle of claim 1, wherein the anisotropic lipid is mannosylerythritol lipids (MEL).
The transdermal absorption micelle of claim 1, wherein the cell permeable peptide is a Tat peptide (Transactivator of transcription peptide).
The transdermal absorption micelle according to claim 1, wherein an average particle diameter of the micelle is 20-100 nm.
The transdermal absorption micelle according to claim 1, wherein the content of the anisotropic lipid is 5 to 40% by weight based on the total weight of the amphiphilic copolymer and the anisotropic lipid.
The transdermal absorption micelle according to claim 2, wherein the content of the cell permeable peptide is 50 μM to 200 μM.
The transdermal absorption cosmetic composition containing the transdermal absorption micelle of any one of Claims 1-9.
The transdermal absorption cosmetic composition according to claim 10, wherein the cosmetic composition is an emulsion, lotion, cream, solution, suspension, gel, pack or powder formulation.
The transdermal absorption cosmetic composition according to claim 10, wherein the cosmetic composition comprises a transdermal absorption micelle in an amount of 0.1 to 10% by weight based on the weight of the total cosmetic composition.

Images